reports
DBV Technologies annonce son intention de modifier le ratio d'ADS
DBV Technologies annonce son intention de modifier le ratio d'ADS Châtillon, France, le 17 mai 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), une société biopharmaceutique au stade clinique spécialisée dans les options de traitement des allergies alimentaires et d'autres conditions immunologiques dont les besoins médicaux ne sont pas satisfaits (« la Société »), a annoncé aujourd'hui son intention de modifier le ratio de ses American Depositary Shares ("ADS") par ra...
DBV Technologies Announces Plan to Implement ADS Ratio Change
DBV Technologies Announces Plan to Implement ADS Ratio Change Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the...
DBV Technologies Announces Results of its 2024 Combined General Meetin...
DBV Technologies Announces Results of its 2024 Combined General Meeting Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen,...
DBV Technologies annonce les résultats de son Assemblée Générale Mixte...
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024 Châtillon, France, le 16 mai 2024 DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024 Toutes les résolutions proposées à l’Assemblée Générale ont été adoptées DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), une entreprise biopharmaceutique de stade clinique spécialisée dans le développement d’options de traitement des allergies alimentaires et autres affections immunologiques ayant d’importants besoins médicaux non satisfaits, a tenu...
UCB SA: 2 directors
Two Directors at UCB SA sold/bought 4,187 shares at 129.920USD. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Dominic Rose
- Naresh Chouhan
AZN - The Path to 2030 Revenue of >$80bn (BUY, TP £140 [£125], 12pgs)
There has been much investor discussion of the upside potential to consensus that could happen as a result of new long-term revenue guidance at the CMD next Tuesday. We show on a product-by-product basis how Total Revenues could exceed $80bn by 2030. This would imply a 25% U/G to consensus revenue forecasts & considerably more to EPS. We do however caution investors that to get to this revenue forecast, it will require considerable R&D investment and we do not believe that consensus has factored...
- Oscar Haffen Lamm
Additional positive data in adolescents to support Ixchiq label extens...
Valneva reported additional positive phase 3 data for its single-shot Ixchiq vaccine (CHIKV) in adolescents. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of the study VLA1553-321 evaluated the safety and immunogenicity six months (Day 180) after vaccination
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents f...
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (D...
DBV Technologies to Participate in Upcoming Investor Conferences
DBV Technologies to Participate in Upcoming Investor Conferences Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Scie...
Participation de DBV Technologies aux conférences investisseurs en mai
Participation de DBV Technologies aux conférences investisseurs en mai Montrouge, France, le 9 mai Participation de DBV Technologies aux conférences investisseurs en mai DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), une société biopharmaceutique au stade clinique spécialisée dans les options de traitement des allergies alimentaires et d'autres conditions immunologiques présentant d'importants besoins médicaux non satisfaits, a annoncé aujourd'hui que Daniel Tassé, Directeur General de DBV, fera une présentation de l'entreprise lors de deu...
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
BMW BAYERISCHE MOTOREN WERKE AG
G1A GEA GROUP AG
PUM PUMA SE
AFX CARL ZEISS MEDITEC AG
UTDI UNITED INTERNET AG
ALO ALSTOM SA
ELE ENDESA S.A.
GEBN GEBERIT AG
RWE RWE AG
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
RY4C RYANAIR HOLDINGS PLC
RTLL RTL GROUP S.A.
SIX2 SIXT SE
BC8 BECHTLE AG
AMS AMADEUS IT GROUP SA CLASS A
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
RACE FERRARI NV
ABI ANHEUSER-BUSCH INBEV SA/NV
LDO LEONARDO SPA
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
KBX KNORR-BREMSE AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
UN0 UNIPER SE
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
BMW BAYERISCHE MOTOREN WERKE AG
G1A GEA GROUP AG
PUM PUMA SE
AFX CARL ZEISS MEDITEC AG
UTDI UNITED INTERNET AG
ALO ALSTOM SA
ELE ENDESA S.A.
GEBN GEBERIT AG
RWE RWE AG
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
RY4C RYANAIR HOLDINGS PLC
RTLL RTL GROUP S.A.
SIX2 SIXT SE
BC8 BECHTLE AG
AMS AMADEUS IT GROUP SA CLASS A
UCG UNICREDIT S.P.A.
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
RACE FERRARI NV
ABI ANHEUSER-BUSCH INBEV SA/NV
LDO LEONARDO SPA
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
KBX KNORR-BREMSE AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
UN0 UNIPER SE
- Damien Choplain
- Martial Descoutures
AstraZeneca : A consensus that leaves little room for surprising guida...
>The premium can be justified by short-term growth and a well-stocked pipeline - AZN certainly benefits from: i/ attractive short-term core EPS growth for 2023-2027, up 11.5% (+12.7% expected this year), and undoubtedly the most well-stocked pipeline in the industry. These elements partly justify the market premium for its 2025 P/E (+43% vs sector median), leading to a 2023-2027 PEG of 1.6x vs 1.3x for the sector. However, this growth should be more timorous in 2...
- Damien Choplain
- Martial Descoutures
AstraZeneca : Un consensus qui ne laisse que peu de place à une guidan...
>Une prime qui se justifie par une croissance CT et un pipeline exhaustif - AZN bénéficie sans nulle doute i/ d’une croissance CT attractive Core BPA 2023-2027 en hausse de 11.5% (+12.7% att cette année) et d’un pipeline certainement le plus exhaustif de l’industrie. Ces aspects justifient en partie la prime octroyée par le marché en termes de PE 25e (+43% vs médiane sectorielle) conduisant à un PEG 23/27e de 1.6x vs 1.3x pour le secteur. En revanche cette croiss...
DBV Technologies Reports First Quarter 2024 Financial Results and Busi...
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with signif...
DBV Technologies publie ses résultats financiers du premier trimestre ...
DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités Montrouge, France, le 7 mai DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités Recrutement de VITESSE en bonne voie pour l’inclusion du dernier patient au troisième trimestre 2024Nomination de Robert Pietrusko, PharmD, en tant que Directeur des Affaires Règlementaires Trésorerie disponible au 31 mars 2024 totalisant $101.5 millions DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), une ...
- Olfa Taamallah
- Yan Derocles
VLS VALNEVA SE
ELG ELMOS SEMICONDUCTOR SE
NOEJ NORMA GROUP SE
ELIS ELIS SA
SHA SCHAEFFLER AG
KRN KRONES AG
PSPN PSP SWISS PROPERTY AG
SIGHT GENSIGHT BIOLOGICS SA
BEZ BERENTZEN GRUPPE
ASS APPLUS SERVICES S.A.
COFA COFACE SA
JUN3 JUNGHEINRICH AG PREF
IDR INDRA SISTEMAS S.A. CLASS A
TMV TEAMVIEWER AG
HAG HENSOLDT AG
- Olfa Taamallah
- Yan Derocles
VLS VALNEVA SE
ELG ELMOS SEMICONDUCTOR SE
NOEJ NORMA GROUP SE
ELIS ELIS SA
SHA SCHAEFFLER AG
KRN KRONES AG
PSPN PSP SWISS PROPERTY AG
SIGHT GENSIGHT BIOLOGICS SA
BEZ BERENTZEN GRUPPE
ASS APPLUS SERVICES S.A.
COFA COFACE SA
JUN3 JUNGHEINRICH AG PREF
IDR INDRA SISTEMAS S.A. CLASS A
TMV TEAMVIEWER AG
HAG HENSOLDT AG
- Damien Choplain
- Martial Descoutures
Valneva : Disappointing Q1 due to supply constraints – guidance confir...
>Top and bottom line below expectations - Q1 revenues came in 2% lower at € 32.8m (-24% vs cs) with product sales stable at € 32.1m (-21% vs cs). This disappointing performance can mainly be attributed to supply issue for Ixiaro which showed a decline of 5% (-34% vs cs). Dukoral saw sales grow by 10% to € 11.3m (+18% vs cs) underpinned by a recovery in the traveller market. As expected, third-party distribution (-9%, -33% vs Cs) suffered from supply constraints for t...
- Oscar Haffen Lamm
Valneva: reports Q1, full year guidance reiterated
Valneva reported its Q1 2024 results where revenues came in at EUR 32.8m (vs css EUR 43.1m), including product sales of EUR 32.1m, driven by Ixiaro (EUR 16.6m, -4.8%), Dukoral (EUR 11.3m, +10.3%), and third party products (EUR 4.1m, -8.9%). The decrease in Ixiaro sales is mainly attributed by the s
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.